1. Home
  2. ETNB vs ADPT Comparison

ETNB vs ADPT Comparison

Compare ETNB & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETNB
    SELLHOLDBUYas of a day ago
  • ADPT
    SELLHOLDBUYas of a day ago
  • Stock Information
  • Founded
  • ETNB 2018
  • ADPT 2009
  • Country
  • ETNB United States
  • ADPT United States
  • Employees
  • ETNB N/A
  • ADPT N/A
  • Industry
  • ETNB Biotechnology: Pharmaceutical Preparations
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ETNB Health Care
  • ADPT Health Care
  • Exchange
  • ETNB Nasdaq
  • ADPT Nasdaq
  • Market Cap
  • ETNB 867.4M
  • ADPT 929.8M
  • IPO Year
  • ETNB 2019
  • ADPT 2019
  • Fundamental
  • Price
  • ETNB $7.94
  • ADPT $6.39
  • Analyst Decision
  • ETNB Buy
  • ADPT Buy
  • Analyst Count
  • ETNB 7
  • ADPT 4
  • Target Price
  • ETNB $30.33
  • ADPT $6.75
  • AVG Volume (30 Days)
  • ETNB 1.2M
  • ADPT 1.4M
  • Earning Date
  • ETNB 11-07-2024
  • ADPT 02-12-2025
  • Dividend Yield
  • ETNB N/A
  • ADPT N/A
  • EPS Growth
  • ETNB N/A
  • ADPT N/A
  • EPS
  • ETNB N/A
  • ADPT N/A
  • Revenue
  • ETNB N/A
  • ADPT $177,282,000.00
  • Revenue This Year
  • ETNB N/A
  • ADPT $6.48
  • Revenue Next Year
  • ETNB N/A
  • ADPT $18.84
  • P/E Ratio
  • ETNB N/A
  • ADPT N/A
  • Revenue Growth
  • ETNB N/A
  • ADPT N/A
  • 52 Week Low
  • ETNB $6.43
  • ADPT $2.28
  • 52 Week High
  • ETNB $16.63
  • ADPT $7.07
  • Technical
  • Relative Strength Index (RSI)
  • ETNB 47.27
  • ADPT 56.16
  • Support Level
  • ETNB $6.43
  • ADPT $5.81
  • Resistance Level
  • ETNB $8.09
  • ADPT $6.93
  • Average True Range (ATR)
  • ETNB 0.60
  • ADPT 0.50
  • MACD
  • ETNB -0.07
  • ADPT -0.04
  • Stochastic Oscillator
  • ETNB 48.24
  • ADPT 46.35

Stock Price Comparison Chart: ETNB vs ADPT

ETNB
ADPT
AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober0510152025303540455055606570ETNB VS ADPT

About ETNB 89bio Inc.

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use